Publications by authors named "Thomas Balzer"

Claim this Profile
and characterization of Bisphosphocin Nu-3-a novel broad-spectrum antimicrobial compound with high potency against resistant pathogens.
Kelvin Cooper, Kanneganti Murthy, Thomas Balzer, Steve Parkinson, Randy Sleet

Antimicrob Agents Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy.
Janina Boyken, Jessica Lohrke, Axel Treu, Joerg Neddens, Gregor Jost, Thomas Balzer

Radiology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: "Gadolinium Deposition Disease: A New Risk Management Threat".
Chia-Ying Liu, Laura Schöckel, Pamela Habib, Thomas Balzer, Hubertus Pietsch

J Am Coll Radiol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.
Jan Endrikat, Susan Dohanish, Nicolas Schleyer, Susanne Schwenke, Sheela Agarwal, Thomas Balzer

Invest Radiol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signal Intensity Increase in the Central Nervous System after Previous Gadoxetic Acid-enhanced MR Imaging.
Cornelia Harz, Laura Schöckel, Jan Endrikat, Hubertus Pietsch, Thomas Balzer

Radiology· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.
Henrik J Michaely, Manuela Aschauer, Hannes Deutschmann, Georg Bongartz, Matthias Gutberlet, Thomas Balzer

Invest Radiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
Jan Endrikat, Kai Vogtlaender, Susan Dohanish, Thomas Balzer, Josy Breuer

Invest Radiol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Evidence Is There That Gadobutrol Causes Increasing Signal Intensity within the Dentate Nucleus and Globus Pallidus on Unenhanced T1W MRI in Patients with RRMS?
Jacob Agris, Hubertus Pietsch, Thomas Balzer

Eur Radiol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study".
Juan E Gutierrez, Martin Rosenberg, Jörg Seemann, Josy Breuer, Daniel Haverstock, Thomas Balzer

Magn Reson Insights· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
Jan S Endrikat, Susan Dohanish, Thomas Balzer, Josy A M Breuer

J Magn Reson Imaging· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.
Juan E Gutierrez, Martin Rosenberg, Jörg Seemann, Josy Breuer, Daniel Haverstock, Thomas Balzer

Magn Reson Insights· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does intravenous administration of gadoxetate disodium have any effect on breath-hold times.
Karsten Bergmann, Jacob Agris, Thomas Balzer

Radiology· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost impact of diagnostic imaging for lower extremity peripheral vascular occlusive disease.
Joel W Hay, Elizabeth Lawler, Kent Yucel, Amy Guo, Thomas Balzer

Value Health· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.
Renate Hammerstingl, Alexander Huppertz, Josy Breuer, Thomas Balzer, Anthony Blakeborough

Eur Radiol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.
Juha Halavaara, Josy Breuer, Carmen Ayuso, Thomas Balzer, Marie-France Bellin

J Comput Assist Tomogr· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Michael V Knopp, Thomas Balzer, Marc Esser, Franciska K Kashanian, Predip Paul

Invest Radiol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
David A Bluemke, Dushyant Sahani, Marco Amendola, Thomas Balzer, Josy Breuer

Radiology· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.
Andrea Löwe, Thomas Balzer, Uta Hirt

Invest Radiol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.
Alexander Huppertz, Thomas Balzer, Anthony Blakeborough, Josy Breuer, Andrea Giovagnoni

Radiology· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.
Peter Reimer, Thomas Balzer

Eur Radiol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.
Thomas J Vogl, Wolfram Schwarz, Stefan Blume, Michael Pietsch, Kohkan Shamsi, Thomas Balzer

Eur Radiol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver.
Peter Reimer, Markus Müller, Christian Marx, Thomas Balzer

Acad Radiol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient.
Renate Hammerstingl, Stephan Zangos, Wolfram Schwarz, Thomas Rosen, Wolf-Otto Bechstein, Thomas Balzer

Acad Radiol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis